Organization Announcements

Organization Announcements
Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

 

Paul G. Allen Frontiers Group [to 3 Jul 2021]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
News
No new digest content identified.

 

BARDA – U.S. Department of HHS [to 3 Jul 2021]
https://www.phe.gov/about/barda/Pages/default.aspx
News
No new digest content identified.

 

BMGF – Gates Foundation [to 3 Jul 2021]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
Press release
Jun 30, 2021
Gates Foundation Commits $2.1 Billion to Advance Gender Equality Globally
Commitments at the Generation Equality Forum will advance women’s economic empowerment, strengthen health and family planning, and accelerate women in leadership as women suffer disproportionately from the pandemic

 

Bill & Melinda Gates Medical Research Institute [to 3 Jul 2021]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

 

CARB-X [to 3 Jul 2021]
https://carb-x.org/
News
No new digest content identified.

 

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 3 Jul 2021]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions and posting of all segments of Vaccines and Global Health: The Week in Review are available here.
:: [NEW] Informed Consent: A Monthly Review – July 2021 is now posted here

 

CEPI – Coalition for Epidemic Preparedness Innovations [to 3 Jul 2021]
http://cepi.net/
Latest News
Joint COVAX Statement on the Equal Recognition of Vaccines
COVAX 01 Jul 2021
[See COVID above for detail]

From lab to potential jab: Clover’s COVID-19 vaccine story
CEPI’s early investment in Clover has been key to accelerating development and equitable access to this promising vaccine.
COVAX 01 Jul 2021

 

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 3 Jul 2021]
https://cioms.ch/
News; Publications
CIOMS June 2021 Newsletter
The CIOMS June 2021 Newsletter is available here.

 

DARPA – Defense Advanced Research Projects Agency [to 3 Jul 2021
https://www.darpa.mil/news
News
No new digest content identified.

 

Duke Global Health Innovation Center [to 3 Jul 2021]
https://dukeghic.org/
No new digest content identified.

 

EDCTP [to 3 Jul 2021]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
30 June 2021
Annual Report 2020 – focused delivery on promises

 

Emory Vaccine Center [to 3 Jul 2021]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

 

European Vaccine Initiative [to 3 Jul 2021]
http://www.euvaccine.eu/
Latest News
No new digest content identified

 

FDA [to 3 Jul 2021]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements /Selected Details
July 2, 2021 – Coronavirus (COVID-19) Update: July 2, 2021
Today, the FDA authorized the use, under the emergency use authorization (EUA) for the Janssen COVID-19 vaccine, of an additional batch of vaccine drug substance manufactured at the Emergent facility. To date a total of four batches of Janssen drug substance that were manufactured at the Emergent facility have been authorized…

June 29, 2021 – Coronavirus (COVID-19) Update: June 29, 2021
The FDA has sent to Congress its Report on Drug Shortages for Calendar Year 2020, which includes a section on the agency’s drug shortage efforts in response to COVID-19…

 

Fondation Merieux [to 3 Jul 2021]
http://www.fondation-merieux.org/
News, Events
No new digest content identified

 

Gavi [to 3 Jul 2021]
https://www.gavi.org/
News Releases
1 July 2021
6 million children benefitting from the first ever multi-antigen vaccination campaign
[Zimbabwe] Harare, 1 July 2021 – UNICEF, Gavi, the Vaccine Alliance and WHO have partnered with the Ministry of Health and Child Care to launch a new vaccine campaign introducing typhoid conjugate vaccine (TCV) into the routine immunisation schedule across the country.
The TCV campaign, the first of its kind in the region, was made possible through funding from Gavi and the multi-donor Health Development Fund (HDF) supported by the European Union, the United Kingdom, Sweden, Irish Aid and Gavi.
“Before the discovery of antibiotics, typhoid would kill as many as one in five people who contracted it,” said Thabani Maphosa, Managing Director of Country Programmes at Gavi. “The rise of extreme drug resistant typhoid risks bringing us back to levels of mortality not seen since the 19th century, posing a risk to all of us. That’s why typhoid conjugate vaccine is so important and why the government of Zimbabwe deserves praise for introducing this lifesaver into its routine immunisation programme.”
The campaign has integrated TCV with the inactivated polio vaccine (IPV) and human papillomavirus (HPV) vaccination. In addition, children aged 6 to 59 months received a vitamin A supplementation. After the initial campaign, TCV will be administered routinely to all children at 9 months of age to protect them from typhoid fever which has become endemic in Zimbabwe with outbreaks continuing to affect communities, particularly children…

1 July 2021
Joint COVAX Statement on the equal recognition of vaccines
[See COVID above for detail]

 

30 June 2021
Indonesia introduces Pneumococcal Conjugate Vaccine (PCV) across the country
:: Gavi, UNICEF and partners collaborate on nationwide introduction, which will see all children from the age of two months protected from pneumonia by 2022
:: The country has received 1.6 million doses of the vaccine procured through the Gavi Pneumococcal Advanced Market Commitment mechanism
:: Anuradha Gupta: “Congratulations to the Government of Indonesia on this milestone, which will save the lives of thousands of children across the country for years to come”

30 June 2021
Gavi signs agreement with Clover Biopharmaceuticals for supply to COVAX
:: The signed advance purchase agreement (APA) will make up to 414 million doses of the Clover vaccine candidate available to the COVAX Facility, pending WHO Emergency Use Listing (EUL)
:: Supply will be available to self-financing participants of the COVAX Facility as well as lower-income economies eligible to be supported by the Gavi COVAX Advance market Commitment (AMC), expected to commence Q4 2021

27 June 2021
US-donated vaccine deliveries through COVAX set to begin, with first shipment to Honduras
:: Deliveries of US-donated doses through COVAX to begin today
:: Anticipated delivery of the Moderna vaccine to Honduras comes after announcements by President Biden of significant dose-sharing pledges; further deliveries to follow in coming days and weeks

 

GHIT Fund [to 3 Jul 2021]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 212 with the aim of developing new tools to tackle infectious diseases that
No new digest content identified.

 

Global Fund [to 3 Jul 2021]
https://www.theglobalfund.org/en/news/
News & Stories
News
WHO and Global Fund Sign Cooperation Agreement to Scale Up HIV, TB and Malaria Interventions and Strengthen Health Systems
30 June 2021
The World Health Organization and the Global Fund to Fight AIDS, Tuberculosis and Malaria signed a cooperation and financing agreement to implement 10 strategic initiatives to accelerate the end of AIDS, tuberculosis and malaria as epidemics and strengthen systems for health. This new agreement, which will cover the 2021-2023 implementation period, aims to address some of the persistent challenges that impede progress against the three diseases and protect hard-won gains from new pandemics like COVID-19.
In 2019, a total of 1.4 million people died from tuberculosis and an estimated 409,000 people died from malaria. In 2020, 690,000 people died from AIDS-related illnesses…

 

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 3 Jul 2021]
https://www.glopid-r.org/news/
News
No new digest content identified.

 

Hilleman Laboratories [to 3 Jul 2021]
http://www.hillemanlabs.org/
Website reports “under maintenance” at inquiry

 

Human Vaccines Project [to 3 Jul 2021]
http://www.humanvaccinesproject.org/
News
News webpage not responding at inquiry

 

IAVI [to 3 Jul 2021]
https://www.iavi.org/newsroom
Latest News
No new digest content identified.

 

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

 

ICRC [to 3 Jul 2021]
https://www.icrc.org/en/whats-new
Selected News Releases, Statements, Reports
Sexual Violence, Conflict, and COVID-19: An Invisible Pandemic
Despite clear legal prohibitions, sexual violence remains widespread during armed conflicts and other situations of violence, as well as in detention. It occurs in various contexts and has grave humanitarian consequences.
24-06-2021 | Article

The challenges for humanitarian action in today’s conflicts: the perspective from the International Committee of the Red Cross
Excellencies, colleagues.It is a pleasure to address you today and I extend my warm appreciation to Minister of Defence Sergey Shoygu.
23-06-2021 | Statement

 

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

 

 

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

 

IFRC [to 3 Jul 2021]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Africa
As COVID-19 cases surge in Africa, Red Cross warns that insufficient funding is impeding the response
Nairobi/Geneva, 2 July 2021 – Halting an increasing trend of COVID-19 cases in Africa will require additional funding. This was announced by the International Federation of Red Cross and Red Crescent Societies (IFRC), amid a worrying surge of cases in …
2 July 2021

Blind spots continue to prevent access to COVID-19 vaccines for refugees and migrants, new Red Cross and Red Crescent report says
Geneva, 30 June 2021 – New research conducted by the Red Cross Red Crescent Global Migration Lab across more than 50 countries reveals that refugees and migrants continue to face serious obstacles in accessing COVID-19 vaccines. Despite some progress m …
30 June 2021

Indonesia
Indonesia: On edge of catastrophe as COVID-19 overwhelms hospitals
Kuala Lumpur/Jakarta/Geneva, 29 June 2021: Urgent increases are needed in medical care, testing and vaccinations as Indonesia teeters on the edge of a COVID-19 catastrophe. The more dangerous and deadly Delta COVID-19 variant is fuelling infections tha …
29 June 2021

 

Institut Pasteur [to 3 Jul 2021]
https://www.pasteur.fr/en/press-area
Press Documents
Press Info
01.07.2021
Modelling study of benefits and risks associated with the COVID-19 vaccine Vaxzevria
On April 7, 2021, the European Medical Agency (EMA) concluded that thrombosis in combination with thrombocytopenia has…

Press release
29.06.2021
Neonatal meningitis: the immaturity of microbiota and epithelial barriers implicated
Meningitis is associated with high mortality and frequently causes severe sequelae. Newborn infants are particularly…

 

IOM / International Organization for Migration [to 3 Jul 2021]
http://www.iom.int/press-room/press-releases
News
IOM’s Emergency Director Urges Swift, Durable Solutions to Protracted Rohingya Crisis
2021-06-29 16:08
Cox’s Bazar – Almost 900,000 Rohingya refugees in congested camps in Bangladesh’s Cox’s Bazar District desperately need urgent action to secure their future, nearly four years after they were forced to flee Myanmar, a senior International Organization for…

 

IVAC [to 3 Jul 2021]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
Johns Hopkins Launches ‘Vira’ Vax ChatBot
July 2021
COVID-19 vaccination is lagging in young adults nationally. Vira, the Vax Chatbot is designed to support and meet young people where they are with simple answers to common COVID-19 vaccine questions. Vira is adaptive, learning by listening to your questions and feedback to help scientists respond to emerging questions. […]

 

IVI [to 3 Jul 2021]
http://www.ivi.int/
Selected IVI News, Announcements, Events
No new digest content identified.

 

JEE Alliance [to 3 Jul 2021]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 

Johns Hopkins Center for Health Security [to 3 Jul 2021]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
Johns Hopkins Center for Health Security Shares Recommendations to Improve Nation’s Public Health and Medical Preparedness and Response Programs
June 28, 2021 – As the U.S. Congress continues to respond to and begin recovery from the COVID-19 pandemic, they must also prepare for the next pandemic, which could appear at any time. For over 20 years, the Johns Hopkins Center for Health Security has worked to protect people’s health from epidemics and disasters and ensure community resilience by examining how innovations, policies, and programs can strengthen health security.
The Center has identified 13 proposals that, if empowered through bipartisan legislation, would improve the nation’s public health, and increase medical preparedness and response programs for future public health events.
Proposals:
Expedite Development of Medical Countermeasures for Unknown Viral Threats
Invest in Ongoing and Just-in-Time Social Science Research to Ensure Public Support for Outbreak Management
Authorize the National Center for Epidemic Forecasting and Outbreak Analytics
Prioritize Funding for Development of At-Home Diagnostic Technology
Support Innovation and Stockpile Strategies to Provide Better Respiratory Protective Devices
Create a National Center for Pandemic and Disaster Nursing Research
Develop New Vaccine Delivery Platforms to Rapidly Immunize Millions in a Pandemic
Develop a National Strategy to Combat Health-Related Misinformation and Disinformation
Create Deployable Research Response Teams
Create a Central Repository for Serosurveys and Public Health Observational Studies
Evaluate the Hospital Preparedness Program’s Effectiveness during the Pandemic
Enlist the Community Health Sector in Achieving Adequate Preparedness and Response for Vulnerable Populations
Develop a Coherent Strategy and Substructure to Facilitate Comprehensive Recovery from an Infectious Disease Disaster
Read full summaries of the proposals.

 

MSF/Médecins Sans Frontières [to 3 Jul 2021]
http://www.msf.org/
Latest [Selected Announcements]
Coronavirus COVID-19 pandemic
COVID-19 pandemic threatens to deteriorate in Brazil as 500,000 deaths recorded
Project Update 30 Jun 2021
As the weather gets colder in Brazil and the pandemic rolls on, the COVID-19 situation in the country has again become deeply concerning, with national and international experts warning of a third devastating wave.
The response remains fragmented and decentralised while the central authorities continue to disregard science, including the importance of masks and physical distancing, in their health messaging.
Sadly, Brazilians now account for over 500,000 COVID-19 deaths and the average COVID-19 fatality rate has crept above 2,000 people a day for the first time since May. Likewise, the number of new cases has also risen to more than 70,000 a day. This is the highest average since the peak of cases during the second wave in early May…

 

National Academy of Medicine – USA [to 3 Jul 2021]
https://nam.edu/programs/
Selected News/Programs
No new digest content identified.

 

National Vaccine Program Office – U.S. HHS [to 3 Jul 2021]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

 

NIH [to 3 Jul 2021]
http://www.nih.gov/news-events/news-releases
News Releases
NIH COVID-19 testing initiative funds additional research projects to safely return children to in-person school
July 2, 2021 — The awards are the second installment of the Safe Return to School Diagnostic Testing Initiative.

Investigational malaria vaccine gives strong, lasting protection
June 30, 2021 — Phase 1 trials conducted at NIH Clinical Center.
Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs—an approach termed chemoprophylaxis vaccination. A Phase 2 clinical trial of the vaccine is now underway in Mali, a malaria-endemic country. If the approach proves successful there, chemoprophylaxis vaccination, or CVac, potentially could help reverse the stalled decline of global malaria. Currently, there is no vaccine in widespread use for the mosquito-transmitted disease.
The trials were conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. They were led by Patrick E. Duffy, M.D., of the NIH National Institute of Allergy and Infectious Diseases (NIAID), and Stephen L. Hoffman, M.D., CEO of Sanaria Inc., Rockville, Maryland.
The Sanaria vaccine, called PfSPZ, is composed of sporozoites, the form of the malaria parasite transmitted to people by mosquito bites. Sporozoites travel through blood to the liver to initiate infection…

NIH-funded screening study builds case for frequent COVID-19 antigen testing
June 30, 2021 — Rapid antigen tests perform on par with lab tests when used every three days.

Adjuvant developed with NIH funding enhances efficacy of India’s COVID-19 vaccine
June 29, 2021 — Adjuvants are formulated as part of a vaccine to boost immune responses and enhance effectiveness.

 

PATH [to 3 Jul 2021]
https://www.path.org/media-center/
Press Releases
PATH announces new five-year strategy
June 29, 2021—PATH announced the launch of a new strategy that will guide the organization’s efforts over the next five years.
The result of a year-long development process that included input from more than 400 local stakeholders across 50 countries, PATH Strategy 2025 aims to respond to current global crises, to the needs and priorities of PATH’s local partners, and to their resounding call for more equitable and inclusive approaches to global public health.
“Our new strategy is very exciting, not only for PATH, but for our entire sector. Over the next five years, we will transform PATH into an even better agent of change for global health,” said Nikolaj Gilbert, President and CEO of PATH.
PATH Strategy 2025 outlines three main priorities: preparing for and responding to emerging health threats, improving lives with science and technology, and increasing health system capacity and resilience.
The five-year plan also outlines four change strategies—equity in health, community-focused priorities, respectful partnerships, and inclusive innovation—that will shape how PATH approaches its work. To learn more about PATH Strategy 2025, visit path.org/strategy2025.

PATH welcomes introduction of the US International Pandemic Preparedness and COVID-19 Response Act of 2021
June 29, 2021 by PATH

 

Sabin Vaccine Institute [to 3 Jul 2021]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

 

UNAIDS [to 3 Jul 2021]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
1 July 2021
Report shows big COVID-19-related HIV prevention programme service disruptions, but highlights that HIV service innovations and adaptations are possible

30 June 2021
UNAIDS, IOM: People on the move living with HIV must have access to COVID-19 vaccines
[See COVID above for detail]

28 June 2021
The journey towards comprehensive sexuality education

 

UNHCR Office of the United Nations High Commissioner for Refugees [to 3 Jul 2021]
http://www.unhcr.org/en-us/media-centre.htmlS
Selected News Releases, Announcements
Refugee health challenges remain high amid COVID-19
1 Jul 2021
Malaria remained the single most common cause of illness among refugees in 2020, while psychological distress caused by COVID-19, and acute malnutrition constituted major threats to refugees’ health and well-being, according to data released today by UNHCR, the UN Refugee Agency, in its Annual Public Health Global Review.
In a year marked by the pandemic, UNHCR’s key focus was to advocate for the inclusion of refugees in COVID-19 national response plans. The agency also worked to support national health systems by procuring personal protective equipment, other equipment like oxygen concentrators, COVID-19 tests and medicines, and by increasing intensive care capacity in countries such as Lebanon and Bangladesh…

 

United Nations Human Rights Council [to 3 Jul 2021]
https://www.ohchr.org/EN/HRBodies/HRC/Pages/NewsSearch.aspx?NTID=PRS&MID=HR_COUNCIL
Council News
COVID, State surveillance, smartphones, mega tech-corporations and artificial intelligence are only a few of the themes which will remain recurrent throughout the life of the mandate on privacy
02/07/2021

Access to reliable information sources is the obvious antidote to disinformation, Special Rapporteur on freedom of opinion and expression tells Human Rights Council
02/07/2021

COVID-19 Pandemic Brought on a Substantive Setback for Persons with Leprosy who must be Recognised as a Vulnerable Group with Regard to Vaccination, Special Rapporteur Tells Human Rights Council
01/07/2021

 

UNICEF [to 3 Jul 2021]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
News note 07/01/2021
UNICEF signs COVID-19 vaccine supply agreement with Janssen Pharmaceutica NV
COPENHAGEN/NEW YORK, 1 July 2021 – UNICEF has signed a long-term agreement with Janssen Pharmaceutica NV for the supply of COVID-19 vaccine on behalf of the COVAX Facility.
Through the supply agreement, UNICEF, along with procurement partners including the Pan-American Health Organization (PAHO), will have access to up to 200 million doses of the single-dose vaccine in 2021 for 92 countries supported by the Advance Market Commitment and also some self-financing countries.  This is the 6th such agreement that UNICEF has completed for COVID-19 vaccines, previous agreements have been announced with the Serum Institute of India, Pfizer, AstraZeneca, Human Vaccine and Moderna…

Press release 07/01/2021
Billions of people will lack access to safe water, sanitation and hygiene in 2030 unless progress quadruples – warn WHO, UNICEF
Latest estimates reveal that 3 in 10 people worldwide could not wash their hands with soap and water at home during the COVID-19 pandemic

Statement 07/01/2021
Joint COVAX statement on the equal recognition of vaccines
[See COVID above for detail]

Press release 06/30/2021
Indonesia introduces pneumococcal conjugate vaccine (PCV) across the country
:: Gavi, UNICEF and partners collaborate on nationwide introduction, which will see all children from the age of two months protected from pneumonia by 2022
:: The country has received 1.6 million doses of the vaccine procured through the Gavi Pneumococcal Advanced Market Commitment mechanism
:: Anuradha Gupta: “Congratulations to the Government of Indonesia on this milestone, which will save the lives of thousands of children across the country for years to come”

Statement 06/27/2021
Statement on U.S. donation of 1.5 million doses of COVID-19 vaccine to Honduras
Statement by Jean Gough, UNICEF Regional Director for Latin America and the Caribbean
PANAMA CITY, 27 June 2021 – “UNICEF welcomes the first United States Government donation of COVID-19 vaccines via COVAX’s dose-sharing mechanism, arriving today in Honduras, and calls for more largescale vaccine donations, in particular to hard-hit Latin America and the Caribbean.
“With only less than 62,000 Hondurans reportedly fully vaccinated, these 1.5 million doses of vaccine represent long-awaited relief to Honduras, which has one of the lowest vaccination rates in Latin America. Moreover, these doses are a glimmer of hope to the region and all countries waiting anxiously for COVAX doses. The United States should be applauded for stepping up to support Honduras, the region, and the world…

 

Unitaid [to 3 Jul 2021]
https://unitaid.org/
Featured News
No new digest content identified.

 

Vaccine Equity Initiative [to 3 Jul 2021]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

 

Vaccination Acceptance & Demand Initiative [Sabin) [to 3 Jul 2021]
https://www.vaccineacceptance.org/
Announcements
No new digest content identified.

 

Vaccine Confidence Project [to 3 Jul 2021]
http://www.vaccineconfidence.org/
News, Research and Reports
Coronavirus global impact
Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 3 Jul 2021]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

 

Wellcome Trust [to 3 Jul 2021]
https://wellcome.ac.uk/news
News and reports
News
From equality to global poverty: the Covid-19 effects on societies and economies
29 June 2021
The Covid-19 pandemic is a social and an economic crisis just as much as it is a health one – its repercussions, severe and far-reaching, are being felt across the world.

 

The Wistar Institute [to 3 Jul 2021]
https://www.wistar.org/news/press-releases
Press Releases
Jun. 29, 2021
Wistar Scientists Discover Blood-based Biomarkers to Predict HIV Remission After Stopping Antiretroviral Therapy
The newly identified sugar and metabolic signatures may help predict duration and probability of HIV remission after antiretroviral therapy interruption during cure-directed clinical trials.

 

WFPHA: World Federation of Public Health Associations [to 3 Jul 2021]
https://www.wfpha.org/
Latest News
Recommendations to Drive Value-based Decision-making in Vaccination
Jun 30, 2021

The Value(S) of Vaccination: Building the Scientific Evidence according to a Value-Based Healthcare Approach
Jun 29, 2021

 

World Bank [to 3 Jul 2021]
http://www.worldbank.org/en/news/all
Selected News, Announcements
Over 350,000 People to Obtain COVID-19 Vaccination in Liberia
WASHINGTON, June 30, 2021 – The World Bank today approved Additional Financing to the Liberia COVID-19 Emergency Preparedness and Response Project to enable affordable and equitable access to COVID-19…
Date: June 30, 2021 Type: Press Release

World Bank Financing for COVID-19 Vaccine Rollout Exceeds $4 Billion for 50 Countries
WASHINGTON, June 30, 2021 – The World Bank announced today that it is providing over $4 billion for the purchase and deployment of COVID-19 vaccines for 51 developing countries, half of which are…
Date: June 30, 2021 Type: Press Release
[See COVID above for detail]

Benin: World Bank Support for the COVID-19 Vaccination Rollout
WASHINGTON, June 29, 2021 – The World Bank has approved $30 million in additional financing from the International Development Association (IDA)* to help Benin vaccinate its population against COVID-19…
Date: June 29, 2021 Type: Press Release

Sudan Gets a Boost from World Bank Group for COVID-19 Response
KHARTOUM, June 29, 2021—The Government of Sudan and the World Bank signed a grant agreement of $100 million to boost the country’s COVID-19 response and expand vaccination coverage in the country. This…
Date: June 29, 2021 Type: Press Release

World Bank Approves $24 Million to Support Zambia with COVID-19 Vaccines
WASHINGTON, June 29, 2021 – The World Bank approved $24 million in additional financing to the Republic of Zambia for the acquisition and equitable distribution of COVID-19 (coronavirus) vaccines. The…
Date: June 29, 2021 Type: Press Release

 

World Customs Organization – WCO [to 3 Jul 2021]
http://www.wcoomd.org/
Latest News – Selected Items
30 June 2021
WCO Deputy Secretary General addresses the WTO Technical Symposium on COVID-19 vaccine supply chain and regulatory transparency
The Deputy Secretary General of the World Customs Organization (WCO), Mr. Ricardo Treviño, joined the Deputy Director-General of the World Trade Organization (WTO), Ms. Anabel González and the Assistant Director-General of the World Health Organization (WHO), Dr. Mariângela Simão in the opening of the WTO Technical Symposium on COVID-19 vaccine supply chain and regulatory transparency that was held online on 29 June 2021.
The Technical Symposium was organized as a follow-up to the WTO event on COVID-19 and vaccine equity that was held on 14 April 2021 with the participation of the WCO Secretary General.
The 29 June 2021 follow-up event was aimed at contributing to improved public and policymaker understanding of the operation of global COVID-19 vaccine supply chains, the cross-border movement of vaccine inputs, and the need for greater regulatory transparency and convergence. The Technical Symposium was also aimed at mapping vaccine production and trade and discussing trade measures that support or constrain the achievement of the rapid scale-up of vaccine production and distribution…

 

World Organisation for Animal Health (OIE) [to 3 Jul 2021]
https://www.oie.int/en/for-the-media/press-releases/2021/
Press Releases
Ten years on, Rinderpest eradication highlights the value of vaccines
News 28 June 2021
The global eradication of Rinderpest gives reason to be optimistic when it comes to fighting infectious animal diseases. While the recent COVID-19 pandemic has shown the devastating impact emerging infectious diseases can have, it is also a reminder of the critical role vaccines can play in protecting us all.
This text was originally published on the iD4D website under Creative Commons BY NC ND 4.0 International

 

WTO – World Trade Organisation [to 3 Jul 2021]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events
Improving trade data for COVID-19 products key to better response policies: WTO
1 July 2021
Improving trade data on products needed to combat the COVID-19 pandemic — including vaccines and their components — is key to ensuring that the right policies are in place to facilitate their distribution, according to a new information note issued by the WTO Secretariat on 1 July.

WTO issues new update on trade in medical goods in the context of COVID-19
30 June 2021
The WTO Secretariat has published a further update of its information note on trade in medical goods in the context of tackling COVID-19. The update provides figures on trade in medical goods covering all of 2020.

World Bank, IMF, WHO, WTO heads call for urgent action to accelerate global vaccine access
30 June 2021
The heads of the World Bank Group, International Monetary Fund, World Health Organization and the WTO convened on 30 June the first meeting of the Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics for Developing Countries. David Malpass, Kristalina Georgieva, Dr Tedros Adhanom Ghebreyesus and Dr Ngozi Okonjo-Iweala said urgent action is needed to stop the rising human toll due to the pandemic and halt further divergence in the economic recovery between advanced economies and the rest. Following the meeting, they issued a joint statement.
[See COVID above for detail]

WTO technical symposium feeds into continuing efforts to deal with COVID-19 pandemic
29 June 2021
The WTO held a technical symposium on 29 June 2021 to address the main challenges to vaccine supply chain and regulatory transparency in the context of COVID-19. Representatives of the medical and pharmaceutical industry, international organizations and the WTO Secretariat explored new ways to cooperate towards finding practical solutions to scale up the global COVID-19 response and address gaps in the global production and distribution of vaccines, personal protective equipment and other medical technologies.
[See COVID above for detail]

::::::

 

ARM [Alliance for Regenerative Medicine] [to 3 Jul 2021]
Press Releases – Alliance for Regenerative Medicine (alliancerm.org)
Selected Press Releases
ARM and NIIMBL Release Project A-Gene to Bring Quality by Design Principles to Gene Therapy Manufacturing
June 24, 2021, Washington, DC
The Alliance for Regenerative Medicine (ARM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) today released Project A-Gene, a multistakeholder collaboration to incorporate Quality by Design (QbD) principles into a manufacturing case study of a viral vector commonly used in gene therapies…

 

BIO [to 3 Jul 2021]
https://www.bio.org/press-releases
Press Releases, Lewtters, Testimony, Comments [Selected]
BIO Letter to USTR Ambassador Tai on Global Vaccine Distribution
June 30, 2021
We would like to provide you some updates on the U.S. and global biotechnology industry’s efforts to scale-up global vaccine production to address the global imbalance in access to COVID vaccines, and to request a close working relationship with…

BIO letter to HHS Secretary Xavier Becerra on the importance of funding R&D for COVID-19 therapeutics at Biomedical Advanced Research and Development Agency (BARDA).
June 25, 2021
The partnership between the biopharmaceutical industry and the U.S. Government is largely responsible for where we are with the COVID-19 pandemic today. In just 16 months from the declaration of the pandemic, cases have dramatically dropped as more…

A Declaration from Members of the World’s Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property
June 24, 2021
[See COVID above for detail]

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 3 Jul 2021]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

 

ICBA – International Council of Biotechnology Associations [to 3 Jul 2021]
https://internationalbiotech.org/news/
News
A Declaration from Members of the World’s Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property
Jul. 01 2021
[See COVID above for detail]

 

IFPMA [to 3 Jul 2021]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

 

International Alliance of Patients’ Organizations – IAPO [to 3 Jul 2021]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

 

PhRMA [to 3 Jul 2021]
http://www.phrma.org/
Latest News [Selected]
3 things that support robust biopharmaceutical research and development
June 29, 2021
Let’s take a closer look at three key pillars of the biopharmaceutical ecosystem that are central to the success of America’s research and development:
1. Private-public collaboration
2. A robust intellectual property (IP) system
3. Strong private sector investment in R&D

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Transgenerational Trauma

AMA Journal of Ethics
Volume 23, Number 6: E435-504 June 2021
https://journalofethics.ama-assn.org/issue/transgenerational-trauma

 

Transgenerational Trauma
One thing that makes trauma transgenerational is narrative. Narrative, for example, is what makes a Confederate flag from 1865 flint for insurrection in 2021. Consequences of global and domestic insults, such as slavery and forced migration, have long ramified intergenerationally in communities, families, and individuals’ bodies. Legacies of trauma travel in stories across places and over time, and their effects include health status inequity and cumulative stress embodiment. Transmission of historically entrenched patterns of oppression also influence persons’ lived experiences of marginalization, convey health risk, and can play out during clinical encounters.

A partisan pandemic: state government public health policies to combat COVID-19 in Brazil

BMJ Global Health
June 2021 – Volume 6 – 6
https://gh.bmj.com/content/6/6

 

A partisan pandemic: state government public health policies to combat COVID-19 in Brazil (3 June, 2021)
Michael Touchton, Felicia Marie Knaul, Héctor Arreola-Ornelas, Thalia Porteny, Mariano Sánchez, Oscar Méndez, Marco Faganello, Vaugh Edelson, Benjamin Gygi, Calla Hummel, Silvia Otero, Jorge Insua, Eduardo Undurraga, Julio Antonio Rosado

Interventions to improve district-level routine health data in low-income and middle-income countries: a systematic review

BMJ Global Health
June 2021 – Volume 6 – 6
https://gh.bmj.com/content/6/6

 

Interventions to improve district-level routine health data in low-income and middle-income countries: a systematic review (11 June, 2021)
Jieun Lee, Caroline A Lynch, Lauren Oliveira Hashiguchi, Robert W Snow, Naomi D Herz, Jayne Webster, Justin Parkhurst, Ngozi A Erondu

Integrated health service delivery during COVID-19: a scoping review of published evidence from low-income and lower-middle-income countries

BMJ Global Health
June 2021 – Volume 6 – 6
https://gh.bmj.com/content/6/6

 

Original research
Integrated health service delivery during COVID-19: a scoping review of published evidence from low-income and lower-middle-income countries (16 June, 2021)
Md Zabir Hasan, Rachel Neill, Priyanka Das, Vasuki Venugopal, Dinesh Arora, David Bishai, Nishant Jain, Shivam Gupta

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 3 Jul 2021)

 

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (…
Authors: Julio Vallejos, Rodrigo Zoni, María Bangher, Silvina Villamandos, Angelina Bobadilla, Fabian Plano, Claudia Campias, Evangelina Chaparro Campias, Maria Fernanda Medina, Fernando Achinelli, Hector Andres Guglielmone, Jorge Ojeda, Diego Farizano Salazar, Gerardo Andino, Pablo Kawerin, Silvana Dellamea…
Citation: BMC Infectious Diseases 2021 21:635
Content type: Research
Published on: 2 July 2021

Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 3 Jul 2021)

 

Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis
The introduction of human papillomavirus (HPV) vaccination has resulted in a remarkable decline of genital warts in women and men, but in Germany historical rates of vaccination are relatively low. We report l…
Authors: Agnieszka Denecke, Thomas Iftner, Angelika Iftner, Sebastian Riedle, Marion Ocak, Alexander Luyten, Isak Üye, Kübra Tunc and Karl Ulrich Petry
Citation: BMC Infectious Diseases 2021 21:634
Content type: Research article
Published on: 2 July 2021

How ethics committees and requirements are structuring health research in the Philippines: a qualitative study

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 3 Jul 2021)

 

How ethics committees and requirements are structuring health research in the Philippines: a qualitative study
The last few decades have seen the rising global acknowledgment of the importance of ethics in the conduct of health research. But research ethics committees or institutional review boards (IRBs) have also bee…
Authors: Gideon Lasco, Vincen Gregory Yu and Lia Palileo-Villanueva
Citation: BMC Medical Ethics 2021 22:85
Content type: Research
Published on: 1 July 2021

Adherence with reporting of ethical standards in COVID-19 human studies: a rapid review

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 3 Jul 2021)

 

Adherence with reporting of ethical standards in COVID-19 human studies: a rapid review
Patients with COVID-19 may feel under pressure to participate in research during the pandemic. Safeguards to protect research participants include ethical guidelines [e.g. Declaration of Helsinki and good clin…
Authors: Lydia O’Sullivan, Ronan P. Killeen, Peter Doran and Rachel K. Crowley
Citation: BMC Medical Ethics 2021 22:80
Content type: Research
Published on: 28 June 2021

Paediatric rotavirus vaccination, coeliac disease and type 1 diabetes in children: a population-based cohort study

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 3 Jul 2021)

 

Paediatric rotavirus vaccination, coeliac disease and type 1 diabetes in children: a population-based cohort study
Rotavirus infection has been proposed as a risk factor for coeliac disease (CD) and type 1 diabetes (T1D). The UK introduced infant rotavirus vaccination in 2013. We have previously shown that rotavirus vaccin…
Authors: Thomas Inns, Kate M. Fleming, Miren Iturriza-Gomara and Daniel Hungerford
Citation: BMC Medicine 2021 19:147
Content type: Research article
Published on: 29 June 2021

Content analysis of digital media coverage of the human papillomavirus vaccine school-entry requirement policy in Puerto Rico

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 3 Jul 2021)

 

Content analysis of digital media coverage of the human papillomavirus vaccine school-entry requirement policy in Puerto Rico
In August 2018, Puerto Rico (PR) became the 4th state or territory in the United States to adopt a human papillomavirus (HPV) vaccine school-entry requirement, for students 11–12 years old. Evidence suggests t…
Authors: Vivian Colón-López, Vilnery Rivera-Figueroa, Glizette O. Arroyo-Morales, Diana T. Medina-Laabes, Roxana Soto-Abreu, Manuel Rivera-Encarnación, Olga L. Díaz-Miranda, Ana P. Ortiz, Katelyn B. Wells, Coralia Vázquez-Otero and Pamela C. Hull
Citation: BMC Public Health 2021 21:1286
Content type: Research article
Published on: 1 July 2021

Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 3 Jul 2021)

 

Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis
Vaccine receipt among mid-adults remains low, with only one quarter of adults being up to date for all recommended vaccines. It is important to understand the myriad factors that influence vaccine receipt amon…
Authors: Mallory K. Ellingson, Carlos R. Oliveira, Sangini S. Sheth, Erin L. Sullivan, Ashlynn Torres, Eugene D. Shapiro and Linda M. Niccolai
Citation: BMC Public Health 2021 21:1283
Content type: Research
Published on: 1 July 2021

Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 3 Jul 2021)

 

Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis
Vaccine receipt among mid-adults remains low, with only one quarter of adults being up to date for all recommended vaccines. It is important to understand the myriad factors that influence vaccine receipt amon…
Authors: Mallory K. Ellingson, Carlos R. Oliveira, Sangini S. Sheth, Erin L. Sullivan, Ashlynn Torres, Eugene D. Shapiro and Linda M. Niccolai
Citation: BMC Public Health 2021 21:1283
Content type: Research
Published on: 1 July 2021

Localisation and local humanitarian action

Humanitarian Exchange Magazine
Number 79, May 2021
https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/

 

Localisation and local humanitarian action
by HPN October 2020
The theme of this edition of Humanitarian Exchange is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies,  non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported.  Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Research ethics during a pandemic (COVID-19)

International Health
Volume 13, Issue 4, July 2021
https://academic.oup.com/inthealth/issue/13/4

 

COMMENTARIES
Research ethics during a pandemic (COVID-19)
Kheng-Wei Yeoh, Ketan Shah
The current pandemic with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a major global health crisis.1 This has put tremendous strain on healthcare systems around the world and naturally raises issues concerning the allocation of scarce resources. It presents a clear and urgent need for research into management of the disease in individuals and of the epidemic in populations. Addressing this need around the world raises practical and ethical issues for the scientific research…

Multicomponent Informed Consent with Marshallese Participants

Journal of Empirical Research on Human Research Ethics
Volume 16 Issue 3, July 2021
http://journals.sagepub.com/toc/jre/current

 

Empirical Studies on Informed Consent
Multicomponent Informed Consent with Marshallese Participants

Rachel S. Purvis, Britni L. Ayers, Cari A. Bogulski, Kyle F. Kaminicki, Lauren K. Haggard-Duff, Lynda A. Riklon, Anita Iban, Rotha Mejbon-Samuel, Rumina Lakmis, Sheldon Riklon, Joseph W. Thompson, Pearl A. McElfish
First Published March 29, 2021; pp. 144–153

Informed Consent for Online Research—Is Anybody Reading?: Assessing Comprehension and Individual Differences in Readings of Digital Consent Forms

Journal of Empirical Research on Human Research Ethics
Volume 16 Issue 3, July 2021
http://journals.sagepub.com/toc/jre/current

 

Informed Consent for Online Research—Is Anybody Reading?: Assessing Comprehension and Individual Differences in Readings of Digital Consent Forms
Caitlin Geier, Robyn B. Adams, Katharine M. Mitchell, Bree E. Holtz
First Published May 24, 2021; pp. 154–164

Boundaries Between Research Ethics and Ethical Research Use in Artificial Intelligence Health Research

Journal of Empirical Research on Human Research Ethics
Volume 16 Issue 3, July 2021
http://journals.sagepub.com/toc/jre/current

 

Special Topic: Ethical issues in Artificial Intelligence (AI) Research
Boundaries Between Research Ethics and Ethical Research Use in Artificial Intelligence Health Research
Gabrielle Samuel, Jenn Chubb, Gemma Derrick
First Published March 18, 2021; pp. 325–337

Overview of the Issue

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 32, Number 2, May 2021 Supplement
https://muse.jhu.edu/issue/44396

 

Table of Contents
Overview of the Issue
Kevin B. Johnson, Tiffani J. Bright, Cheryl R. Clark
…The importance of techquity—defined as the strategic development and deployment of technology in health care and health to advance health equity—was even more apparent after the events of 2020. COVID-19 upended access to care and illuminated the impact of structural racism as a cause for a widening gap of access during the pandemic. Black Lives Matter became more than a trending hashtag on Twitter, or a movement resulting in peaceful protests and calls for policy reform: it put additional focus on the issue of race as a social and not a biological construct and called into question the rationale for common practices in health care that were triggered by race. A notable example was the emerging realization that kidney function assessment was tied to race and hardwired into many of our electronic health records. The real-world evidence around our lack of techquity was incontrovertible.
This Supplemental Issue of JHCPU provides articles that describe challenges to techquity, frameworks to improve the role of technology in care, and examples of how technology can transform health, public health, and health care…

Learning from crisis: building resilient systems to combat future pandemics

The Lancet
Jul 03, 2021 Volume 398 Number 10294 p1-92, e1-e6
https://www.thelancet.com/journals/lancet/issue/current

 

Lecture
Learning from crisis: building resilient systems to combat future pandemics
Ilona Kickbusch, Gabriel M Leung, Robin J Shattock
COVID-19 has accelerated medical research in the quest to understand this new pandemic threat, to answer public health questions, and to develop a vaccine that could allow a return to “normal” life. A spotlight has illuminated how evidence becomes policy, and the interface of politics and science, which encompasses ecological, financial, and social risks, among others. In a lecture delivered for the Academy of Medical Sciences on Nov 2, 2020, we examined the threat of future pandemics in the light of COVID-19, reviewing how to prepare, how to build resilient health systems, and what we can learn from coronavirus to combat pandemics of the future.

International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy

 

Volume 99, Issue 2 Pages: 329-599 June 2021
https://onlinelibrary.wiley.com/toc/14680009/current
Original Scholarship
Open Access
International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility
MARK ECCLESTON-TURNER, HARRY UPTON
Pages: 426-449
First Published: 02 March 2021
Policy Points
:: Equitable access to a COVID-19 vaccine in all countries remains a key policy objective, but experience of previous pandemics suggests access will be limited in developing countries, despite the rapid development of three successful vaccine candidates.
:: The COVAX Facility seeks to address this important issue, but the prevalence of vaccine nationalism threatens to limit the ability of the facility to meet both its funding targets and its ambitious goals for vaccine procurement.
:: A failure to adequately address the underlying lack of infrastructure in developing countries threatens to further limit the success of the COVAX Facility.

Allocating a COVID-19 Vaccine: Balancing National and International Responsibilities

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy

 

Perspectives
Free Access
Allocating a COVID-19 Vaccine: Balancing National and International Responsibilities
REIDAR K. LIE, FRANKLIN G. MILLER
Pages: 450-466
First Published: 09 December 2020
Policy Points
:: In this paper we propose a middle-ground policy for the distribution of an effective COVID-19 vaccine, between a cosmopolitan approach that rejects entirely nation-state priority and unbridled vaccine nationalism that disregards obligations to promote an equitable global allocation of an effective vaccine over time.
:: Features of the COVAX partnership, a collaboration among the Global Alliance for Vaccines and Immunizations (GAVI), the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO) to develop and distribute COVID-19 vaccines make it an appropriate framework for a middle-ground policy.

Covid-19 and the Investigator Pipeline

New England Journal of Medicine
July 1, 2021 Vol. 385 No. 1
http://www.nejm.org/toc/nejm/medical-journal

 

Perspective
Covid-19 and the Investigator Pipeline
Katrina Armstrong, M.D., M.S.C.E.
… Emerging infectious diseases and other health threats will continue to pose a danger to the United States and the global community. It’s time to leverage vaccine-development efforts to take on another important Covid-related challenge: stabilizing the investigator pipeline. As recent months have shown, the scientific pipeline is both in jeopardy and central to our ability to address emerging health threats.

Incentives for Immunity — Strategies for Increasing Covid-19 Vaccine Uptake

New England Journal of Medicine
July 1, 2021 Vol. 385 No. 1
http://www.nejm.org/toc/nejm/medical-journal

 

Incentives for Immunity — Strategies for Increasing Covid-19 Vaccine Uptake
Kevin G. Volpp, M.D., Ph.D., and Carolyn C. Cannuscio, Sc.D.
… Incentives alone are unlikely to deliver the population immunity that will end the pandemic. The series of million-dollar jackpots that is being deployed in Ohio is an intriguing alternative to test, but it is unclear whether this will be a widely embraced approach. We need to go further in adopting a combination of behaviorally informed policies that will protect our health and the health of the economy for years to come.

Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 3 Jul 2021)

 

Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial
Sheila Isanaka, Céline Langendorf, Monica Malone McNeal, Nicole Meyer, Brian Plikaytis, Souna Garba, Nathan Sayinzoga-Makombe, Issaka Soumana, Ousmane Guindo, Rockyiath Makarimi, Marie Francoise Scherrer, Eric Adehossi, Iza Ciglenecki, Rebecca F. Grais
Research Article | published 02 Jul 2021 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003655

Worldviews, trust, and risk perceptions shape public acceptance of COVID-19 public health measures

PNAS – Proceedings of the National Academy of Sciences of the United States of America
June 15, 2021; vol. 118 no. 24
https://www.pnas.org/content/118/24

 

Psychological and Cognitive Sciences
Worldviews, trust, and risk perceptions shape public acceptance of COVID-19 public health measures
Michael Siegrist and Angela Bearth
PNAS June 15, 2021 118 (24) e2100411118; https://doi.org/10.1073/pnas.2100411118
Significance
The successful implementation of measures aimed at reducing the number of people infected with COVID-19 crucially depends on public acceptance of these measures. We show that it is not gender or age but psychological variables, such as trust and worldviews, that strongly influence people’s risk perceptions and acceptance of the measures. We are able to show these effects in both cross-sectional and longitudinal study designs. Since the acceptance of implemented measures crucially depends on whether they are in line with people’s values and worldviews, the latter two variables are as relevant as epidemiological facts for successful risk management.

Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests

Vaccine
Volume 39, Issue 26 Pages 3455-3536 (11 June 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/26

 

Discussion No access
Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests
Nir Eyal, Tobias Gerhard, Brian L. Strom
Pages 3455-3458

Minimising missed opportunities to promote and deliver immunization services to middle and older age adults: Can hospital-based programs be a solution?

Vaccine
Volume 39, Issue 26 Pages 3455-3536 (11 June 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/26

 

Research article Abstract only
Minimising missed opportunities to promote and deliver immunization services to middle and older age adults: Can hospital-based programs be a solution?
Kathleen McFadden, Anita Heywood, Amalie Dyda, Jessica Kaufman, Holly Seale
Pages 3467-3472

Older adults’ vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake

Vaccine
Volume 39, Issue 26 Pages 3455-3536 (11 June 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/26

 

Research article Open access
Older adults’ vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake
Louise A. Brown Nicholls, Allyson J. Gallant, Nicola Cogan, Susan Rasmussen, … Lynn Williams
Pages 3520-3527

Patient and clinician factors associated with uptake of the human papillomavirus (HPV) vaccine among adolescent patients of a primary care network

Vaccine
Volume 39, Issue 26 Pages 3455-3536 (11 June 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/26

 

Research article Abstract only
Patient and clinician factors associated with uptake of the human papillomavirus (HPV) vaccine among adolescent patients of a primary care network
Julie H.T. Dang, Susan L. Stewart, Dean A. Blumberg, Hector P. Rodriguez, Moon S. Chen
Pages 3528-3535

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
The sheer volume of vaccine and pandemic-related coverage is extraordinary. We will strive to present the most substantive analysis and commentary we encounter.

 

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 3 Jul 2021
[No new, unique, relevant content]

 

BBC
http://www.bbc.co.uk/
Accessed 3 Jul 2021
[No new, unique, relevant content]

 

The Economist
http://www.economist.com/
Accessed 3 Jul 2021
After the disease
The long goodbye to covid-19
The pandemic is still far from over, but glimpses of its legacy are emerging
Jul 3, 2021
WHEN WILL it end? For a year and a half, covid-19 has gripped one country after another. Just when you think the virus is beaten, a new variant comes storming back, more infectious than the last. And yet, as the number of vaccinations passes 3bn, glimpses of post-covid life are emerging. Already, two things are clear: that the last phase of the pandemic will be drawn-out and painful; and that covid-19 will leave behind a different world…

 

Financial Times
https://www.ft.com/
Coronavirus latest: Fourth of July travel projected to near record high
Brazil’s top prosecutor opens investigation into Bolsonaro over vaccine deal
July 2, 2021

Coronavirus latest: Michigan’s $5m vaccine lottery draws 500,000 applicants in first day
Michigan’s $5m vaccine lottery draws 500,000 applicants in first day
July 2, 2021

Coronavirus: White House sets up ‘surge response teams’ to tackle Delta hotspots – as it happened
Africa’s head of vaccine procurement hits out at EU for hoarding jabs
July 1, 2021

 

Forbes
http://www.forbes.com/
Accessed 3 Jul 2021
[No new, unique, relevant content]

 

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 3 Jul 2021
[No new, unique, relevant content]

 

Foreign Policy
http://foreignpolicy.com/
Accessed 3 Jul 2021
[No new, unique, relevant content]

 

New Yorker
http://www.newyorker.com/
Accessed 3 Jul 2021
[No new, unique, relevant content]

 

New York Times
http://www.nytimes.com/
Accessed 3 Jul 2021
World
These are the U.S. states trying lotteries to increase Covid vaccinations.
By Adeel Hassan and Andrea Kannapell 3 July 2021

Middle East
Iran’s president warns of a potential fifth wave as the Delta variant spreads.
By Jesus Jiménez 3 July 2021

Americas
Brazil Vaccine Scandal Imperils Bolsonaro as Protests Spread
Brazilians were angry over how slowly their government moved to acquire coronavirus vaccines. Now they’re incensed over a corruption scandal involving vaccine deals.
By Ernesto Londoño and Flávia Milhorance 3 July 2021

 

Washington Post
https://www.washingtonpost.com/
Accessed 3 Jul 2021
[No new, unique, relevant content]

Think Tanks et al

Think Tanks et al
 
 
Brookings
http://www.brookings.edu/
Accessed 3 Jul 2021
TechTank
Vaccine passports underscore the necessity of U.S. privacy legislation
Nicol Turner Lee, Samantha Lai, and Emily Skahill
Monday, June 28, 2021
 
 
Center for Global Development [to 3 Jul 2021]
http://www.cgdev.org/page/press-center
Publication
Plus ça change: COVID-19 and Its Collateral Impact during the Vaccine Era
July 1, 2021
Over the past year we partnered with researchers in Kenya, the Philippines, South Africa, and Uganda to document, from a whole-of-health perspective, what we know about the nature, scale, and scope of COVID-19’s disruptions to essential health services in those countries, and the health effects of such disruptions. In a working paper released today, we build on a blog we published in March when we released working papers from each country team (the papers are available here: Kenya, the Philippines, South Africa, Uganda). In this new working paper, we summarize the results and lessons across the four countries in more detail.  We also tie together many of the blogs we have written on this topic over the past year (this series of blogs can be found here).
Damian Walker et al.
 
 
Chatham House [to 3 Jul 2021]
https://www.chathamhouse.org/
Accessed 3 Jul 2021
[No new digest content identified]

 
 
CSIS
https://www.csis.org/
Accessed 3 Jul 2021
Blog Post
Covid-19’s Toll on Youth in Southeast Asia
July 2, 2021

Podcast Episode
Richard Hatchett on CEPI in the Covid-19 Era
July 1, 2021 | By J. Stephen Morrison

Transcript
CEPI 2.0: A Critical Inflection Point
June 29, 2021

Transcript
The Reality of Rolling Out COVID-19 Vaccines
June 29, 2021

Commentary
The CPTPP and Intellectual Property Rights Protection
June 28, 2021 | By Joanna Shelton

 
 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
June 30, 2021 News Release
Workers Are More Likely to Get a COVID-19 Vaccine When Their Employers Encourage It and Provide Paid Sick Leave, Though Most Workers Don’t Want Their Employers to Require It
A Third of Parents with Kids Ages 12-17 Report Their Kids Are Now Vaccinated; Most Parents Oppose Mandatory Vaccinations for School Children As more employers return to in-person work, the latest KFF COVID-19 Vaccine Monitor report shows that workers are more likely to have gotten a COVID-19 vaccine when their…
 
 
Urban Institute [to 3 Jul 2021]
https://www.urban.org/publications
Publications
COVID-19 Vaccine Attitudes among Nonelderly Adults Who Reported Being Unlikely to Get Vaccinated
Adults’ decisionmaking about getting the COVID-19 vaccines is complex. This brief provides qualitative insights from interviews conducted in February 2021 with 40 nonelderly adults who reported in the Urban Institute’s December 2020 Well-Being and Basic Needs Survey (WBNS) that they would probably or definitely not get a COVID-19 vaccine. Our key findings are as follows: As of February 2021, most interviewees
Dulce Gonzalez, Haley Samuel-Jakubos, Brigette Courtot, Clara Alvarez Caraveo, Joshua Aarons
June 21, 2021
Brief

Vaccines and Global Health: The Week in Review :: 26 June 2021

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version A pdf of the current issue is available here: 

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Gavi Board strengthens commitment to reaching the most vulnerable through routine immunisation and COVAX :: What does COVAX’s latest supply forecast tell us?

Milestones :: Perspectives :: Research

 

Editor’s Note:
These Gavi announcements represent critical milestones in COVID response and, as such, we present their full text.

Gavi Board strengthens commitment to reaching the most vulnerable through routine immunisation and COVAX
:: Gavi Board makes key strategic decisions to support Gavi’s 5.0 strategy of leaving no child behind through immunisation; doubles down on ambitious targets for COVAX
:: New market-shaping strategy, alliances with civil society among measures aimed at reducing the number of children receiving no doses of vaccine, by 25% globally – by 2025 
:: US$ 775 million in COVAX delivery funding approved for lower-income economies that are eligible for support through the Gavi COVAX Advance Market Commitment (AMC)
:: José Manuel Barroso: “Protecting the most vulnerable and enabling access to the lifesaving power of vaccines has always been at the heart of Gavi’s mission. As Africa, with the lowest vaccine coverage in the world, and other regions face a renewed surge of the virus, the global community must step up now to help COVAX to meet its ambitious equitable access goals to support these countries.”

Geneva, 25 June 2021 – The Board of Gavi, the Vaccine Alliance has made several decisions to strengthen the organisation’s commitment to protecting the most vulnerable everywhere – through routine immunisation, access to COVID-19 vaccines via the Gavi-hosted COVAX Facility and support for outbreak preparedness and response activities.

In addition to taking decisions relating to Gavi’s strategic direction, the Board united in condemning today’s gross inequity in vaccine delivery and committed itself to redoubling efforts to close the gap.

“Protecting the most vulnerable and enabling equitable access to lifesaving vaccines has always been at the heart of Gavi’s mission,” said José Manuel Barroso, Chair of the Gavi Board. “As Africa, with the lowest vaccine coverage in the world, and other regions face a renewed surge of the virus, we must use all our resourcefulness and innovation to help those most at risk: the global community must step up now to help COVAX to meet its ambitious equitable goals to support these countries.”

 

Supporting COVAX to deliver 
Earlier this week COVAX, the world’s first global procurement facility for pandemic vaccines, released an updated supply forecast demonstrating that, thanks to new agreements with manufacturers and dose-sharing by higher income economies, supplies were expected to reach two billion doses in January 2022 – only a short time later than previous forecasts, despite severe on-going supply delays. According to the forecast, COVAX’s goal of delivering 1.8 billion doses to lower-income economies eligible for donor-supported doses via the Gavi COVAX Advance Market Commitment (COVAX AMC) would be reached in the first quarter of 2022.

In order to help prepare countries for this rapid scale up, the Gavi Board approved new funding of US$ 775 million to support the delivery of COVAX-funded doses in lower-income economies and humanitarian zones over the next two years. Gavi is co-lead of COVAX and hosts the Office of the COVAX Facility. The funding comes in addition to a previously Board-approved envelope of US$ 150 million in delivery support.

The Board also approved an evolution in the model of participation for self-financing participants (SFPs) of the COVAX Facility. Starting in 2022, the model will enable SFPs that rely on the Facility to access doses to continue procuring vaccines through COVAX under revised terms and conditions. The move, based on lessons learned over the past year, will enable simplified operations and reduce financial risks to Gavi and COVAX.

“As the only global solution designed around equitable access to COVID-19 vaccines, we need to continue to adapt the COVAX model as the pandemic evolves,” said Dr Seth Berkley, CEO of Gavi. “The additional delivery support funding will help make sure that COVAX-funded doses are rapidly and efficiently rolled out in lower-income economies. But it will not help us end the acute phase of pandemic alone: to do this, we need governments, manufacturers and multilateral development banks to truly get behind COVAX and get us doses now so we can scale up protecting lives and do so quickly.”

 

Reaching the most vulnerable with routine immunisation
Many decisions at the two-day board meeting concerned Gavi’s new 5.0 strategy.

Guiding the Alliance’s mission over the period 2021–2025, Gavi 5.0’s goal is to “leave no one behind with immunisation”, with a core focus on reaching “zero-dose” children and missed communities, with equity as the organising principle. 

The following decisions are aimed at providing a critical framework for achieving this goal – building on Gavi’s existing strengths, as well as forming new partnerships and evolving key policies:
:: A measurement framework for the work of the Alliance in the next five years. In line with its 5.0 overarching objective of leaving no one behind, Gavi will aim to reduce the number of zero-dose children globally by 25% in 2021–2025. Other indicators include immunising an additional 300 million children and preventing 7-8 million future deaths through Gavi’s support for routine immunisation programmes and vaccination campaigns, while unlocking US$ 80-100 billion in economic benefits.

:: A 2021-2025 Market Shaping Strategy that will foster a sustainable, competitive future supplier base by encouraging healthy demand through a more coordinated and country-centric approach. The strategy will also focus on enabling vaccine product innovations that best meet country needs and that directly contribute to the Gavi 5.0 goals of increasing equitable vaccine coverage and reaching zero-dose children and missed communities.

:: The Civil Society and Community Engagement Approach to ensure effective management, enhanced capacity and efficient funding of Gavi’s engagement with civil society organisations (CSOs). Beyond their comparative advantage in reaching zero-dose children and missed communities, CSOs have key roles to play in helping to ensure immunisation is maintained, restored and strengthened in the context of COVID-19, and that vaccines are introduced in an equitable way.

:: An initial investment of up to US$ 5 million for the Vaccine Innovation Prioritisation Strategy (VIPS) for costs related to short-term (2021–2023) activities to provide guidance for and incentivise development of three innovation priorities, including clarifying the potential demand, defining investment cases and understanding the need for and design of push and pull funding mechanisms, as well as generating evidence of programmatic impact.

:: Yellow Fever diagnostic capacity strengthening initially to create the first commercial test kits for Yellow Fever, which has been accomplished, and support for costs related to the procurement and distribution of laboratory reagents, supplies and equipment which has been extended until the end of 2022. The costs remain within the initially approved envelope of US$ 8.2 million authorised for the 2019–2021 period.

:: An approach to strengthen fiduciary risk assurance and financial management of Gavi grants in the 5.0 strategic period, with associated investment of US$ 139 million for 2022–2025. As Gavi funding will increasingly be channelled through government systems, the investments will be used to help build sustainable financial management capacity of government systems, as well as ensure the continued use of fiduciary risk mitigation mechanisms.

Encompassing both COVAX and Gavi 5.0 is Gavi’s risk appetite statement, which defines the criteria and trade-off considerations that guide the Alliance’s appetite for risk at the mission, strategy and organisational level. Against the backdrop of the ongoing COVID-19 pandemic, the Board approved an approach where the Alliance will seek to find the right balance between successfully delivering on the COVAX mission, where Gavi plays a central role, while minimising risks to Gavi’s core resources and programmes, acknowledging the reality that a higher risk appetite is needed in a pandemic setting.

 

Key departures and appointments
The Board approved a one-year exceptional contract extension for Gavi CEO Dr Seth Berkley to guarantee stable and strong leadership of the Alliance in this critical time and ensure successful implementation of COVAX and Gavi 5.0. The current CEO’s 3rd term will now end in August 2023 and succession planning will be led by Gavi Board Chair.

The Board also welcomed new Board members including Awa Marie Coll Seck, Naguib Kheraj and Bounfeng Phoummalaysith.

In addition, the Board thanked Stephen Zinser and Muhammad Ali Pate as their terms as Board members concluded. Stephen Zinser has been a Gavi Board member since 2014 and has guided Gavi’s transition through two strategic periods. Muhammad Ali Pate began his term as a Board member in July 2019 lending his counsel and extensive experience to support the work of the Alliance. Mr Pate has also been an invaluable member of Market Sensitive Decisions Committee (MSDC) since October 2019.

Finally, the Gavi Board gave a warm send-off to Bill Roedy. Mr Roedy joined Gavi in 2010 as its first envoy. He was appointed to the Board in 2015 and has been Board Vice Chair in 2018–2019. Mr Roedy is recognised as a global health leader who has used his extensive network and experience to champion both Gavi and immunisation.

 

::::::

What does COVAX’s latest supply forecast tell us?
23 June 2021 – by Aurélia Nguyen, Managing Director, Office of the COVAX Facility

COVAX’s latest supply forecast is now published. According to this latest assessment, the vaccines pillar of the ACT-Accelerator will have 1.9 billion doses available for supply by the end of 2021 and, thanks to a number of recently signed advance purchase agreements, now has signed deals in place for a total of 2.8 billion doses in 2021 and 2022, with a further 1.3 billion secured should it need them. This is due in large part to the pledges made by donors to the Gavi COVAX AMC.

The forecast is encouraging given the supply disruptions COVAX and countries with bilateral deals are currently experiencing, as well as the general challenges manufacturers are experiencing as they ramp up supply at historic speed and scale. But what does it mean in the context of COVAX’s stated goal of ending the acute phase of the pandemic? Unsurprisingly, given that it represents the most ambitious roll-out of vaccines in history, the numbers in the document provide some important insights.

 

Short term supply concerns persist
The first observation is that, despite remaining more or less on target for its original year-end goal to make 2 billion doses available to participants, COVAX deliveries will continue to be very lean through July and August. This is a result of a number of well-documented factors, including the diversion of production at the Serum Institute of India (SII), an important early supplier, to meet acute domestic needs, as well as challenges scaling up deliveries across AstraZeneca’s global manufacturing network and fulfilling requirements to enable delivery of the Pfizer vaccine – COVAX’s other two currently active suppliers.

 

Dose sharing is becoming an important immediate-term source of doses
In response to COVAX’s call to countries with excess supply to help alleviate short term supply shortages by sharing doses, a number of donors have now stepped forward. According to the forecast, 515 million doses have been pledged, and they should start becoming available in significant numbers very soon, with 80 million expected by the end of July and a total of 115 million by the end of August. Apart from the period between September and October when 100 million dose donations are expected to come online, supply from countries’ pledges are anticipated to be relatively evenly paced through the year, with around 40-50 million donated doses available each month until the end of December.

 

Absorptive capacity is a very real concern
The reason why COVAX has been urging donors to share doses in the third quarter rather than later in the year is to avoid the possibility of COVAX participants’ health systems becoming too stretched by the volume of deliveries later in the year. COVAX’s partners work closely with countries in the Facility, especially the 92 lower-income economies eligible for support through the Gavi COVAX AMC, to ensure conditions are in place to enable mass vaccination. From September onwards, the forecast projects that a number in the region of 400 million doses will become available every month so it’s critical that sufficient funding is unlocked, where necessary, to help countries prepare for this.

 

COVAX will keep on doing deals
COVAX has currently signed deals for 2.8 billion doses. This is more than enough to fulfil our goal of delivering 1.8 billion doses to AMC economies as well as supplying the approximately 480 million doses ordered by self-financing economies. A key reason COVAX has signed deals and options for more doses is to allow participants that want to receive more doses to procure them through cost-sharing; taking advantage of COVAX’s pricing and access, plus other advantages such as its no-fault compensation scheme, to raise protection rates in their countries further. COVAX’s goal from the beginning has also been to build a portfolio of 10-12 vaccines to ensure suitability for all contexts and to mitigate risks around over-reliance on specific sources in case there are issues related to failure at the R&D stage, regulatory hurdles or supply challenges. Gavi, on behalf of the Facility, also negotiates key flexibilities such as options and potential access to future variant-adapted vaccines to ensure the Facility portfolio can continue to be tailored to participants’ evolving needs. To this end, expect further advance purchase agreements to be announced in the coming weeks and months.

 

Mind the gap (between availability and deliveries)
One important distinction between the supply forecast and COVAX’s delivery tracker, which is hosted by COVAX’s key delivery partner UNICEF, is that the forecast tracks the availability of doses at the manufacturer. With a number of technical, regulatory and legal tasks to be overcome before doses can be released, there is always a delay between doses becoming available and being shipped and delivered to countries. Although COVAX partners work closely with countries, manufacturers and other stakeholders to minimise this gap, the estimated timings shown here reflect the availability of doses at the manufacturer and not in country.

 

The Supply Forecast will continue to evolve
There are a number of other caveats worth noting in the forecast too, all of which relate to the scale and number of moving pieces across COVAX’s unprecedented end-to-end solution. The timing of regulatory approval, for example, can be volatile, especially since it is common that more than one manufacturing site is involved in the supply chain. Likewise local licensing or export controls can and have had an impact on supply schedules. For these reasons as well as the fact that more secured doses are expected to be added to its portfolio, COVAX will aim to keep this forecast updated as regularly as possible through 2021 and beyond. Watch this space

UNHCR calls on states to remove barriers to access to COVID-19 vaccines for refugees

Milestones :: Perspectives :: Research

 

UNHCR calls on states to remove barriers to access to COVID-19 vaccines for refugees
24 June 2021
Four months since the first delivery of COVID-19 vaccines from the COVAX facility, the global initiative to ensure the vaccines’ equitable distribution, UNHCR, the UN Refugee Agency, calls on States to expedite the roll-out of vaccination campaigns and remove barriers that limit access to vaccines for the world’s 82.4 million forcibly displaced people.

UNHCR is monitoring the inclusion of refugees and asylum seekers in COVID-19 vaccination plans and roll-out in 162 countries.

Of the 126 countries with a refugee population of more than 500 people, UNHCR has confirmed that 123 have either explicitly included refugees in their vaccination plans or provided assurances that they will do so. This is also the case for asylum-seekers in 93 out of 96 countries.

Moreover, UNHCR is able to confirm that refugees and asylum-seekers have begun receiving COVID-19 vaccinations in 91 of the 162 countries monitored. UNHCR commends the States that have included these forcibly displaced populations in the vaccine roll-out and urges others to follow their lead.
“Around the world, we have seen an unwavering commitment to not leave refugees behind in COVID-19 vaccination planning,” said Ann Burton, Chief of UNHCR’s Public Health Section. “But barriers to vaccination persist. Stronger efforts are needed to ensure that States’ assurances for refugee inclusion turn into tangible reality.”

To register for or receive vaccinations, some States require identity documents which refugees often do not have. Others have set up online systems that can deter or prevent people without access to the Internet or who are not computer literate from registering for vaccines.

In several countries, vaccination sites are located far from where refugees live, which could deter them from seeking immunization. This is the case particularly in Sub-Saharan Africa, where newly reported COVID-19 cases are on the rise, in contrast to the observable decline in many parts of the world.
Other factors that prevent people from getting vaccinated include the real or perceived cost of the vaccine services, language barriers, as well as lack of information, misinformation and limited opportunities to ask questions, which can lead to vaccine hesitancy.

UNHCR welcomes the efforts of States to overcome these hurdles. Moldova and Serbia prioritized bringing the vaccine to people living in asylum centers, while in Serbia vaccination is completed for refugees living in private accommodation as well. Senegal and Cameroon allowed refugees to register in designated health facilities and city councils in the vicinity of their communities. Portugal introduced a specific registration system for undocumented persons to ensure that no one is excluded from the vaccine roll-out. Meanwhile, in the Democratic Republic of the Congo (DRC) the region’s largest awareness-raising campaign on COVID-19 has reached more than 1.7 million people since the beginning of the pandemic.

UNHCR stands ready to work with all States to ensure at least 20 per cent of refugees are vaccinated by the end of 2021, as per the target set by COVAX. The Agency also urges States with surplus vaccine doses to share them with lower and middle-income countries and to support the COVAX facility.
“Beyond the moral imperative, this is in our collective self-interest,” said Burton. “As long as the pandemic remains out of control somewhere, it is threat for everyone everywhere.”

WHO supporting South African consortium to establish first COVID mRNA vaccine technology transfer hub

Milestones :: Perspectives :: Research

 

WHO supporting South African consortium to establish first COVID mRNA vaccine technology transfer hub
Geneva/Johannesburg/Paris: The World Health Organization (WHO) and its COVAX partners are working with a South African consortium comprising Biovac, Afrigen Biologics and Vaccines, a network of universities and the Africa Centres for Disease Control and Prevention (CDC) to establish its first COVID mRNA vaccine technology transfer hub.

The move follows WHO’s global  call for Expression of Interest (EOI) on 16 April 2021 to establish COVID mRNA vaccine technology transfer hubs to scale up production and access to COVID vaccines. Over the coming weeks, the partners will negotiate details with the Government of South Africa and public and private partners inside the country and from around the world.

South African President Cyril Ramaphosa said: “The COVID-19 pandemic has revealed the full extent of the vaccine gap between developed and developing economies, and how that gap can severely undermine global health security. This landmark initiative is a major advance in the international effort to build vaccine development and manufacturing capacity that will put Africa on a path to self determination. South Africa welcomes the opportunity to host a vaccine technology transfer hub and to build on the capacity and expertise that already exists on the continent to contribute to this effort.”

“This is great news, particularly for Africa, which has the least access to vaccines,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “COVID-19 has highlighted the importance of local production to address health emergencies, strengthen regional health security and expand sustainable access to health products.”

…Technology transfer hubs are training facilities where the technology is established at industrial scale and clinical development performed. Interested manufacturers from low- and middle-income countries can receive training and any necessary licenses to the technology. WHO and partners will bring in the production know-how, quality control and necessary licenses to a single entity to facilitate a broad and rapid technology transfer to multiple recipients.

The technology transfer hub will benefit from the Medicines Patent Pool’s (MPP’s) vast experience of intellectual property (IP) management and issuing of IP licenses. MPP is also assisting WHO to negotiate with technical partners and supporting in the governance of the hubs…